Physician profile
David L Luterman
NPI 1629079751
$12,493.99
in general payments reported to CMS, 2019-2025
49 companies · $1,369 in 2025
The $1,369 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,039 · 2020: $675 · 2021: $1,952 · 2022: $1,980 · 2023: $2,207 · 2024: $1,272 · 2025: $1,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,770 · Education: $77.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,770.47 |
| Education | $77.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,271.26 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,633.81 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,544.66 | 2019-2025 | Ofev, Jascayd |
| Mylan Specialty L.P. | $844.51 | 2019-2024 | Yupelri |
| Insmed, INC. | $738.99 | 2019-2025 | Arikayce, Brinsupri |
| Resmed Corp | $555.61 | 2019-2022 | |
| Harmony Biosciences LLC | $554.74 | 2020-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $509.99 | 2019-2024 | |
| Grifols USA, LLC | $339.28 | 2019-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $324.19 | 2019-2023 | Dupixent |
| Mallinckrodt Hospital Products INC. | $298.44 | 2021-2024 | Acthar |
| Genzyme Corporation | $190.03 | 2021-2025 | |
| Ucb, INC. | $176.13 | 2019-2021 | |
| Zoll Respicardia, INC. | $174.86 | 2023 | Remede System |
| Teva Pharmaceuticals USA, INC. | $158.82 | 2019-2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Luterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.